Merck’s Zontivity Label Isn’t Weighed Down With Safety Language
This article was originally published in The Pink Sheet Daily
FDA approves antiplatelet inhibitor with a label that makes little mention of the safety concerns seen in lightweight patients, despite a vibrant FDA and advisory panel discussion on how to present the unfavorable data, but the company still has a big marketing challenge ahead.
You may also be interested in...
Diabetics seem to have benefited from Zetia, but not rest of high-risk patients in IMPROVE-IT – suggesting next-step cholesterol drugs might wind up being targeted to subgroups.
Novartis’s Cosentyx and Celgene’s Otezla are expected to be approved and launched in Europe in early 2015 for the dermatological indication.
Large, complex dataset supporting Merck’s vorapaxar NDA invited “slicing and dicing” of the data by the primary reviewers – and made weight-based restrictions a key issue at the late-cycle and advisory committee meetings. But unusual, late-in-the-game reviews by high level FDA officials led to a post-panel U-turn.